The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Second Sight has an asset utilization ratio of 1.76 percent. This connotes that the company is making $0.0176 for each dollar of assets. An increasing asset utilization means that Second Sight is more efficient with each dollar of assets it utilizes for everyday operations.
The successful prediction of Second Sight
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as Second Sight Medical, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of Second Sight based on Second Sight hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to Second Sight's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Second Sight's related companies.
Use Technical Analysis to project Second expected Price
Second Sight technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, delisted stock market cycles, or different charting patterns.
A focus of Second Sight technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Second Sight trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...What is driving Second Sight Investor Appetite?
The latest price spike of Second Sight could raise concerns from retail investors as the company it trading at a share price of
5.79 on
737,528,000 in volume. The company directors and management may have good odds in positioning the company resources to exploit market volatility in
April. The stock standard deviation of daily returns for 30 days investing horizon is currently 39.99. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Second Sight partners.
Deferred Revenue Breakdown
Second Sight Deferred Revenue yearly trend continues to be relatively stable with very little volatility. Deferred Revenue is likely to grow to about 309.4
K this year. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Second Sight Deferred Revenue is relatively stable at the moment as compared to the past year. Second Sight reported last year Deferred Revenue of 301,500
| 2014 | 4.67 Million |
| 2015 | 2.52 Million |
| 2016 | 189,000 |
| 2017 | 48,000 |
| 2018 | 167,000 |
| 2019 | 335,000 |
| 2020 | 301,500 |
| 2021 | 309,434 |
Another 3 percent spike for Second Sight
Second Sight latest semi variance advances over 60.16.
As of the 6th of March, Second Sight has the Coefficient Of Variation of 1145.35,
semi deviation of 7.76, and Risk Adjusted Performance of 0.0773. Second Sight
technical analysis provides you with a way to harness past market data to determine a pattern that measures the direction of the company's future prices. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to analyze and collect data for nineteen
technical drivers for Second Sight, which can be compared to its competition. Please validate
Second Sight standard deviation, as well as the
relationship between the maximum drawdown and
expected short fall to decide if Second Sight is priced more or less accurately, providing market reflects its prevalent price of 5.79 per share. Given that Second Sight has
jensen alpha of 1.04, we advise you to double-check Second Sight's current market performance to make sure the company can sustain itself at a future point.
Our Final Takeaway
While some firms under the medical devices industry are still a bit expensive, Second Sight may offer a potential longer-term growth to retail investors. While some retail investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Second Sight.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Second Sight Medical. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
